Structure-function relationship of lipoprotein lipase-mediated enhancement of very low density lipoprotein binding and catabolism by the low density lipoprotein receptor. Functional importance of a properly folded surface loop covering the catalytic center
We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density lipoproteins (VLDL) in COS cells. Untransfected COS cells did not bind to or catabolize normal VLDL. Expression of wild-type hLPL by transient t...
Saved in:
| Published in | The Journal of biological chemistry Vol. 271; no. 36; pp. 21906 - 21913 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
06.09.1996
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-9258 1083-351X |
| DOI | 10.1074/jbc.271.36.21906 |
Cover
| Abstract | We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density lipoproteins (VLDL) in COS cells. Untransfected COS cells did not bind to or catabolize normal VLDL. Expression of wild-type hLPL by transient transfection enhanced binding, uptake, and degradation of the VLDL (a property of LPL that we call bridge function). Heparin pretreatment and a monoclonal antibody ID7 that blocks LDL receptor-binding domain of apoE both inhibited binding, and apoE2/E2 VLDL from a Type III hyperlipidemic subject did not bind. However, LDL did not reduce 125I-VLDL binding to the hLPL-expressing cells, whereas rabbit p-VLDL was an effective competitor. By contrast, LDL reduced uptake and degradation of 125I-VLDL to the same extent as excess unlabeled VLDL or beta-VLDL. These data suggest that binding occurs by direct interaction of VLDL with LPL but the subsequent catabolism of the VLDL is mediated by the LDL receptor. Mutant hLPLs that were catalytically inactive, S132A, S132D, as well as the partially active mutant, S251T, and S172G, gave normal enhancement of VLDL binding and catabolism, whereas the partially active mutant S172D had markedly impaired capacity for the process; thus, there is no correlation between bridge function and lipolytic activity. A naturally occurring genetic variant hLPL, S447 replaced by Ter, has normal bridge function. The catalytic center of LPL is covered by a 21-amino acid loop that must be repositioned before a lipid substrate can gain access to the active site for catalysis. We studied three hLPL loop mutants (LPL-cH, an enzymatically active mutant with the loop replaced by a hepatic lipase loop; LPL-cP, an enzymatically inactive mutant with the loop replaced by a pancreatic lipase loop; and C216S/C239S, an enzymatically inactive mutant with the pair of Cys residues delimiting the loop substituted by Ser residues) and a control double Cys mutant, C418S/C438S |
|---|---|
| AbstractList | We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density lipoproteins (VLDL) in COS cells. Untransfected COS cells did not bind to or catabolize normal VLDL. Expression of wild-type hLPL by transient transfection enhanced binding, uptake, and degradation of the VLDL (a property of LPL that we call bridge function). Heparin pretreatment and a monoclonal antibody ID7 that blocks LDL receptor-binding domain of apoE both inhibited binding, and apoE2/E2 VLDL from a Type III hyperlipidemic subject did not bind. However, LDL did not reduce 125I-VLDL binding to the hLPL-expressing cells, whereas rabbit p-VLDL was an effective competitor. By contrast, LDL reduced uptake and degradation of 125I-VLDL to the same extent as excess unlabeled VLDL or beta-VLDL. These data suggest that binding occurs by direct interaction of VLDL with LPL but the subsequent catabolism of the VLDL is mediated by the LDL receptor. Mutant hLPLs that were catalytically inactive, S132A, S132D, as well as the partially active mutant, S251T, and S172G, gave normal enhancement of VLDL binding and catabolism, whereas the partially active mutant S172D had markedly impaired capacity for the process; thus, there is no correlation between bridge function and lipolytic activity. A naturally occurring genetic variant hLPL, S447 replaced by Ter, has normal bridge function. The catalytic center of LPL is covered by a 21-amino acid loop that must be repositioned before a lipid substrate can gain access to the active site for catalysis. We studied three hLPL loop mutants (LPL-cH, an enzymatically active mutant with the loop replaced by a hepatic lipase loop; LPL-cP, an enzymatically inactive mutant with the loop replaced by a pancreatic lipase loop; and C216S/C239S, an enzymatically inactive mutant with the pair of Cys residues delimiting the loop substituted by Ser residues) and a control double Cys mutant, C418S/C438S. Two of the loop mutants (LPL-cH and LPL-cP) and the control double Cys mutant C418S/ C438S gave normal enhancement of VLDL binding and catabolism, whereas the third loop mutant, C216S/ C239S, was completely inactive. We conclude that although catalytic activity and the actual primary sequence of the loop of LPL are relatively unimportant (wild-type LPL loop and pancreatic lipase loops have little sequence similarity), the intact folding of the loop, flanked by disulfide bonds, must be maintained for LPL to express its bridge function. We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density lipoproteins (VLDL) in COS cells. Untransfected COS cells did not bind to or catabolize normal VLDL. Expression of wild-type hLPL by transient transfection enhanced binding, uptake, and degradation of the VLDL (a property of LPL that we call bridge function). Heparin pretreatment and a monoclonal antibody ID7 that blocks LDL receptor-binding domain of apoE both inhibited binding, and apoE2/E2 VLDL from a Type III hyperlipidemic subject did not bind. However, LDL did not reduce 125I-VLDL binding to the hLPL-expressing cells, whereas rabbit beta-VLDL was an effective competitor. By contrast, LDL reduced uptake and degradation of 125I-VLDL to the same extent as excess unlabeled VLDL or beta-VLDL. These data suggest that binding occurs by direct interaction of VLDL with LPL but the subsequent catabolism of the VLDL is mediated by the LDL receptor. Mutant hLPLs that were catalytically inactive, S132A, S132D, as well as the partially active mutant, S251T, and S172G, gave normal enhancement of VLDL binding and catabolism, whereas the partially active mutant S172D had markedly impaired capacity for the process; thus, there is no correlation between bridge function and lipolytic activity. A naturally occurring genetic variant hLPL, S447-->Ter, has normal bridge function. The catalytic center of LPL is covered by a 21-amino acid loop that must be repositioned before a lipid substrate can gain access to the active site for catalysis. We studied three hLPL loop mutants (LPL-cH, an enzymatically active mutant with the loop replaced by a hepatic lipase loop; LPL-cP, an enzymatically inactive mutant with the loop replaced by a pancreatic lipase loop; and C216S/C239S, an enzymatically inactive mutant with the pair of Cys residues delimiting the loop substituted by Ser residues) and a control double Cys mutant, C418S/C438S. Two of the loop mutants (LPL-cH and LPL-cP) and the control double Cys mutant C418S/C438S gave normal enhancement of VLDL binding and catabolism, whereas the third loop mutant, C216S/C239S, was completely inactive. We conclude that although catalytic activity and the actual primary sequence of the loop of LPL are relatively unimportant (wild-type LPL loop and pancreatic lipase loops have little sequence similarity), the intact folding of the loop, flanked by disulfide bonds, must be maintained for LPL to express its bridge function.We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density lipoproteins (VLDL) in COS cells. Untransfected COS cells did not bind to or catabolize normal VLDL. Expression of wild-type hLPL by transient transfection enhanced binding, uptake, and degradation of the VLDL (a property of LPL that we call bridge function). Heparin pretreatment and a monoclonal antibody ID7 that blocks LDL receptor-binding domain of apoE both inhibited binding, and apoE2/E2 VLDL from a Type III hyperlipidemic subject did not bind. However, LDL did not reduce 125I-VLDL binding to the hLPL-expressing cells, whereas rabbit beta-VLDL was an effective competitor. By contrast, LDL reduced uptake and degradation of 125I-VLDL to the same extent as excess unlabeled VLDL or beta-VLDL. These data suggest that binding occurs by direct interaction of VLDL with LPL but the subsequent catabolism of the VLDL is mediated by the LDL receptor. Mutant hLPLs that were catalytically inactive, S132A, S132D, as well as the partially active mutant, S251T, and S172G, gave normal enhancement of VLDL binding and catabolism, whereas the partially active mutant S172D had markedly impaired capacity for the process; thus, there is no correlation between bridge function and lipolytic activity. A naturally occurring genetic variant hLPL, S447-->Ter, has normal bridge function. The catalytic center of LPL is covered by a 21-amino acid loop that must be repositioned before a lipid substrate can gain access to the active site for catalysis. We studied three hLPL loop mutants (LPL-cH, an enzymatically active mutant with the loop replaced by a hepatic lipase loop; LPL-cP, an enzymatically inactive mutant with the loop replaced by a pancreatic lipase loop; and C216S/C239S, an enzymatically inactive mutant with the pair of Cys residues delimiting the loop substituted by Ser residues) and a control double Cys mutant, C418S/C438S. Two of the loop mutants (LPL-cH and LPL-cP) and the control double Cys mutant C418S/C438S gave normal enhancement of VLDL binding and catabolism, whereas the third loop mutant, C216S/C239S, was completely inactive. We conclude that although catalytic activity and the actual primary sequence of the loop of LPL are relatively unimportant (wild-type LPL loop and pancreatic lipase loops have little sequence similarity), the intact folding of the loop, flanked by disulfide bonds, must be maintained for LPL to express its bridge function. We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density lipoproteins (VLDL) in COS cells. Untransfected COS cells did not bind to or catabolize normal VLDL. Expression of wild-type hLPL by transient transfection enhanced binding, uptake, and degradation of the VLDL (a property of LPL that we call bridge function). Heparin pretreatment and a monoclonal antibody ID7 that blocks LDL receptor-binding domain of apoE both inhibited binding, and apoE2/E2 VLDL from a Type III hyperlipidemic subject did not bind. However, LDL did not reduce 125I-VLDL binding to the hLPL-expressing cells, whereas rabbit p-VLDL was an effective competitor. By contrast, LDL reduced uptake and degradation of 125I-VLDL to the same extent as excess unlabeled VLDL or beta-VLDL. These data suggest that binding occurs by direct interaction of VLDL with LPL but the subsequent catabolism of the VLDL is mediated by the LDL receptor. Mutant hLPLs that were catalytically inactive, S132A, S132D, as well as the partially active mutant, S251T, and S172G, gave normal enhancement of VLDL binding and catabolism, whereas the partially active mutant S172D had markedly impaired capacity for the process; thus, there is no correlation between bridge function and lipolytic activity. A naturally occurring genetic variant hLPL, S447 replaced by Ter, has normal bridge function. The catalytic center of LPL is covered by a 21-amino acid loop that must be repositioned before a lipid substrate can gain access to the active site for catalysis. We studied three hLPL loop mutants (LPL-cH, an enzymatically active mutant with the loop replaced by a hepatic lipase loop; LPL-cP, an enzymatically inactive mutant with the loop replaced by a pancreatic lipase loop; and C216S/C239S, an enzymatically inactive mutant with the pair of Cys residues delimiting the loop substituted by Ser residues) and a control double Cys mutant, C418S/C438S We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density lipoproteins (VLDL) in COS cells. Untransfected COS cells did not bind to or catabolize normal VLDL. Expression of wild-type hLPL by transient transfection enhanced binding, uptake, and degradation of the VLDL (a property of LPL that we call bridge function). Heparin pretreatment and a monoclonal antibody ID7 that blocks LDL receptor-binding domain of apoE both inhibited binding, and apoE2/E2 VLDL from a Type III hyperlipidemic subject did not bind. However, LDL did not reduce 125I-VLDL binding to the hLPL-expressing cells, whereas rabbit beta-VLDL was an effective competitor. By contrast, LDL reduced uptake and degradation of 125I-VLDL to the same extent as excess unlabeled VLDL or beta-VLDL. These data suggest that binding occurs by direct interaction of VLDL with LPL but the subsequent catabolism of the VLDL is mediated by the LDL receptor. Mutant hLPLs that were catalytically inactive, S132A, S132D, as well as the partially active mutant, S251T, and S172G, gave normal enhancement of VLDL binding and catabolism, whereas the partially active mutant S172D had markedly impaired capacity for the process; thus, there is no correlation between bridge function and lipolytic activity. A naturally occurring genetic variant hLPL, S447-->Ter, has normal bridge function. The catalytic center of LPL is covered by a 21-amino acid loop that must be repositioned before a lipid substrate can gain access to the active site for catalysis. We studied three hLPL loop mutants (LPL-cH, an enzymatically active mutant with the loop replaced by a hepatic lipase loop; LPL-cP, an enzymatically inactive mutant with the loop replaced by a pancreatic lipase loop; and C216S/C239S, an enzymatically inactive mutant with the pair of Cys residues delimiting the loop substituted by Ser residues) and a control double Cys mutant, C418S/C438S. Two of the loop mutants (LPL-cH and LPL-cP) and the control double Cys mutant C418S/C438S gave normal enhancement of VLDL binding and catabolism, whereas the third loop mutant, C216S/C239S, was completely inactive. We conclude that although catalytic activity and the actual primary sequence of the loop of LPL are relatively unimportant (wild-type LPL loop and pancreatic lipase loops have little sequence similarity), the intact folding of the loop, flanked by disulfide bonds, must be maintained for LPL to express its bridge function. |
| Author | Salinelli, S. (Baylor College of Medicine, Houston, TX.) Mims, M.P Lo, J.Y Chan, L Zsigmond, E Smith, L.C |
| Author_xml | – sequence: 1 fullname: Salinelli, S. (Baylor College of Medicine, Houston, TX.) – sequence: 2 fullname: Lo, J.Y – sequence: 3 fullname: Mims, M.P – sequence: 4 fullname: Zsigmond, E – sequence: 5 fullname: Smith, L.C – sequence: 6 fullname: Chan, L |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/8702993$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc1rFjEQh6NU6tvqXQQhp952TTb7kRyl2CoUPNSCtyUfk74p2WRNssr-9-7S9-JBzCUD85t5HpgLdBZiAITeUVJTMrQfn5Sum4HWrK8bKkj_Eh0o4axiHf1xhg6ENLQSTcdfo4ucn8j2WkHP0TkfSCMEO7xA9yUtuiwJKrsEXVwMOIGXe5GPbsbRYu_mOKdYwIW9lhmqCYyTBQyGcJRBwwSh7NFfkFbs429sIGRX1r9mlQvGhUcsg8FaFqmid3nCasXlCP-cSqBhLjHV-OYkKD120xxT2ck7VeItPEPyK7bRm00rL8lKvS-NM9Zx09rBO2YH-7U4jfXmDOkNemWlz_D29F-ih5vP36-_VHffbr9ef7qrbNP1pQJmuQZpVMdJY7UQvG8VbxS1thmAG8O4ZRqI6iTTGqgC0WnTmpbYnoCS7BJdPe_dVH8ukMs4uazBexkgLnkceNOLbuD_DbZckGGgbAt-OAUXtd1jnJObZFrH0223_vvnvpVxlI_J5fHhXgztQLuO_QFWp7rQ |
| ContentType | Journal Article |
| DBID | FBQ CGR CUY CVF ECM EIF NPM 7S9 L.6 7X8 |
| DOI | 10.1074/jbc.271.36.21906 |
| DatabaseName | AGRIS Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitleList | AGRICOLA MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry |
| EISSN | 1083-351X |
| EndPage | 21913 |
| ExternalDocumentID | 8702993 US9747155 |
| Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: HL27341 – fundername: NHLBI NIH HHS grantid: HL16512 – fundername: NHLBI NIH HHS grantid: HL46860 |
| GroupedDBID | --- -DZ -ET -~X .55 .GJ 0SF 186 18M 2WC 3O- 53G 5BI 5GY 5RE 5VS 6TJ 85S AAEDW AAFWJ AARDX AAXUO AAYOK ABDNZ ABOCM ABPPZ ABPTK ABRJW ABTAH ACGFO ACNCT ADBBV ADIYS AENEX AEQTP AEXQZ AFFNX AFMIJ AFOSN AFPKN AI. ALMA_UNASSIGNED_HOLDINGS BTFSW C1A CJ0 CS3 DIK DU5 E3Z EBS EJD F20 F5P FA8 FBQ FDB FRP GROUPED_DOAJ GX1 HH5 IH2 J5H KQ8 L7B MVM N9A NHB OHT OK1 P-O P0W P2P R.V RHF RHI RNS ROL RPM SJN TBC TN5 TR2 UHB UPT UQL VH1 VQA W8F WH7 WHG WOQ X7M XFK XJT XSW Y6R YQT YSK YWH YYP YZZ ZA5 ZGI ZY4 ~02 ~KM 0R~ 79B AALRI ADVLN AITUG AKRWK AMRAJ CGR CUY CVF ECM EIF H13 NPM PKN Z5M .7T 7S9 AAYWO ACVFH ADCNI ADXHL AEUPX AFPUW AIGII AKBMS AKYEP L.6 7X8 |
| ID | FETCH-LOGICAL-f256t-e3f8ceadb5802fc99864b82b1ff27e8dd38f3ce0b5a3cce1be95cd4d40f60eba3 |
| ISSN | 0021-9258 |
| IngestDate | Fri Sep 05 09:56:25 EDT 2025 Thu Sep 04 18:53:03 EDT 2025 Wed Feb 19 02:29:26 EST 2025 Wed Dec 27 19:13:26 EST 2023 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 36 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-f256t-e3f8ceadb5802fc99864b82b1ff27e8dd38f3ce0b5a3cce1be95cd4d40f60eba3 |
| Notes | S20 9747155 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 8702993 |
| PQID | 48907713 |
| PQPubID | 24069 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_78269578 proquest_miscellaneous_48907713 pubmed_primary_8702993 fao_agris_US9747155 |
| PublicationCentury | 1900 |
| PublicationDate | 1996-09-06 |
| PublicationDateYYYYMMDD | 1996-09-06 |
| PublicationDate_xml | – month: 09 year: 1996 text: 1996-09-06 day: 06 |
| PublicationDecade | 1990 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of biological chemistry |
| PublicationTitleAlternate | J Biol Chem |
| PublicationYear | 1996 |
| SSID | ssj0000491 |
| Score | 1.7088033 |
| Snippet | We examined the structure-function relationship of human lipoprotein lipase (hLPL) in its ability to enhance the binding and catabolism of very low density... |
| SourceID | proquest pubmed fao |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 21906 |
| SubjectTerms | ACTIVIDAD CATALITICA ACTIVITE CATALYTIQUE Animals Apolipoprotein B-100 Apolipoproteins B Apolipoproteins B - metabolism Apolipoproteins E Apolipoproteins E - metabolism Binding Sites CATABOLISME CATABOLISMO Catalysis catalytic activity cell lines CHIMIORECEPTEUR Cricetinae Cricetulus CULTIVO DE CELULAS CULTURE DE CELLULE DEGRADACION DEGRADATION Enzyme-Linked Immunosorbent Assay ESTIMULO FIBROBLASTE FIBROBLASTOS fibroblasts GENERO HUMANO genetics GENRE HUMAIN Humans lipoprotein lipase Lipoprotein Lipase - genetics Lipoprotein Lipase - metabolism LIPOPROTEINA LIPASA LIPOPROTEINAS LIPOPROTEINE LIPOPROTEINE LIPASE Lipoproteins, LDL Lipoproteins, LDL - metabolism Lipoproteins, VLDL Lipoproteins, VLDL - metabolism low density lipoprotein metabolism molecular conformation MUTACION MUTANT MUTANTES mutants MUTATION Point Mutation protein degradation Protein Structure, Tertiary PROTEINAS PROTEINE QUIMIORECEPTORES Rabbits receptors Receptors, LDL Receptors, LDL - metabolism site-directed mutagenesis STIMULUS Structure-Activity Relationship Transfection very low density lipoprotein |
| Title | Structure-function relationship of lipoprotein lipase-mediated enhancement of very low density lipoprotein binding and catabolism by the low density lipoprotein receptor. Functional importance of a properly folded surface loop covering the catalytic center |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/8702993 https://www.proquest.com/docview/48907713 https://www.proquest.com/docview/78269578 |
| Volume | 271 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 1083-351X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000491 issn: 0021-9258 databaseCode: HH5 dateStart: 19050101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1083-351X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000491 issn: 0021-9258 databaseCode: KQ8 dateStart: 19051001 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1083-351X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000491 issn: 0021-9258 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1083-351X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000491 issn: 0021-9258 databaseCode: AKRWK dateStart: 19051001 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Jj9MwFIBNGQ5wQdBhRFl9QHOpUrI3PY5GrUbQDkLTShWXyHbsmaI2KV2Eym_nwHt2tulQsVyiKIpjV--r37P9FkLeuTyUdo8llqtsafmB7VtRIAJLce5IgdElOpB2dBleTPwP02DaaPyseS1tN7wjfvw2ruR_pArPQK4YJfsPki0_Cg_gHuQLV5AwXP9Kxlc6-et2JS1UT1qSq8K5DZ2wMgwxXmY6F8MsxXvQWZYOFkFDU6Y3KPPCHQB-_q49z763E3Rqx4oStbZ8ZsJfdBgc2wA6cyyvgcYrgHaoFUyncgmr-k57kA8Qc3wstM2PM4oOzlzieQCmWVbZPIFhrbcrxQR-NFu2BbqYFiFdeq9phylm0ac09yv-WvFes65NcimT_qSoaVfuJjG0recmMLw0hofmDKpd2vajmdmGGlUxcF_Ws-tFXoi5X22YGB9rzLNQVwLoleKajPGFEnBNIZicdm9vTjfN72gbML9Q23DRgeYdL-yUr95O7H35KR5MhsN43J-OT5ffLKx5hr4BeQGY--SB2w1DrL_x8XOV6x7WbqbeYz7c_JAdOn2_3yUYRoplhxdJ2lgaPyGPcznQM4PsU9KQaZMcn6Vsky129JRqv2N9oNMkD88L-RzfI3eJpnWiaaZojS-6RzStEY2vItEU2KQ5m7fa5kRTIJpWRFO-o4DawVYl0bQimlZEY6-MFkRTQzTNiaZINC2I1t2URFND9DMyGfTH5xdWXqPEUrBY2FjSU5GA2ZgHke0q0cNqBzxyuaOU25VRkniR8oS0ecA8IaTDZS8QiZ_4tgptyZl3Qo7SLJXPCXUEzI5g8QeOF_gMVlaOI2QQMLsrelwqp0WaIOSYXYP2jydXuBEAi4EWeVsIPQZh4XEfS2W2Xcd-1LO7Xcc7_AasDsIeqOwWOTG0xEuT4iYGLQ52qvfij01fkkfVf-wVOQJK5Gsw0zf8jab5F0dA_ts |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Structure-function+relationship+of+lipoprotein+lipase-mediated+enhancement+of+very+low+density+lipoprotein+binding+and+catabolism+by+the+low+density+lipoprotein+receptor.+Functional+importance+of+a+properly+folded+surface+loop+covering+the+catalytic+center&rft.jtitle=The+Journal+of+biological+chemistry&rft.au=Salinelli%2C+S&rft.au=Lo%2C+J+Y&rft.au=Mims%2C+M+P&rft.au=Zsigmond%2C+E&rft.date=1996-09-06&rft.issn=0021-9258&rft.volume=271&rft.issue=36&rft.spage=21906&rft_id=info:doi/10.1074%2Fjbc.271.36.21906&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9258&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9258&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9258&client=summon |